Henry Januszewicz

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Timothy P. Hughes, Susan Branford, Deborah L. White et al. · Blood · 2008 · 177 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +10

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma

Andrew Wirth, John F. Seymour, Rodney J. Hicks et al. · The American Journal of Medicine · 2002 · 170 citations

Medicine, Nuclear Medicine, Radiology +13

Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab

Glen Kennedy, John F. Seymour, M Wolf et al. · European Journal Of Haematology · 2003 · 146 citations

Medicine, Hematology, Pharmacology +17

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Simon J. Harrison, Hang Quach, Emma Link et al. · Blood · 2011 · 76 citations

Medicine, Pharmacology, Pharmacotherapy +14

Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy

Chan Y. Cheah, Michael S. Hofman, Michael Dickinson et al. · British Journal of Cancer · 2013 · 68 citations · Full text

Medicine, Nuclear Medicine, Oncology +17